LLY · News · 20261030N

Revenue Performance and Mix

ELI LILLY & Co · 2026-10-30 · Importance 80 · Surprise 68

Mounjaro and Zepbound generated more than $16 billion in combined global sales in Q3 2026, driving Lilly’s quarterly performance. Lilly raised its 2026 revenue guidance to $91 billion–$92 billion. Q3 2026 adjusted earnings were $7.48 per share, up 7% year over year from $7.02.

Key facts

• Eli Lilly's Mounjaro and Zepbound collectively generated over $16 billion in global sales in Q3. source
• Eli Lilly reported third-quarter 2026 non-GAAP earnings of $7.48 per share, 39% above the Zacks Consensus Estimate of $5.38 per share. source
• Eli Lilly's third-quarter 2026 earnings increased 7% year over year from $7.02 per share. source
• Eli Lilly reported third-quarter 2026 adjusted earnings of $7.48 per share, exceeding the Zacks Consensus Estimate of $5.38 per share. source